Cite
Wu X, Zhou H, He Z, et al. Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report. Transl Lung Cancer Res. 2020;9(6):2494-2499doi: 10.21037/tlcr-20-1049.
Wu, X., Zhou, H., He, Z., Zhang, Z., Feng, W., Zhao, J., Chen, H., Wang, S., Wang, W., & Wang, Q. (2020). Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report. Translational lung cancer research, 9(6), 2494-2499. https://doi.org/10.21037/tlcr-20-1049
Wu, Xuan, et al. "Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report." Translational lung cancer research vol. 9,6 (2020): 2494-2499. doi: https://doi.org/10.21037/tlcr-20-1049
Wu X, Zhou H, He Z, Zhang Z, Feng W, Zhao J, Chen H, Wang S, Wang W, Wang Q. Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report. Transl Lung Cancer Res. 2020 Dec;9(6):2494-2499. doi: 10.21037/tlcr-20-1049. PMID: 33489809; PMCID: PMC7815378.
Copy
Download .nbib